Home
Clival Database

Clival Database Market Share Analysis for July 2026

Alto Neuroscience has completed enrollment in its Phase 2 proof-of-concept trial evaluating ALTO-101, a transdermal phosphodiesterase-4 (PDE4) inhibitor, for cognitive impairment associated with schizophrenia (CIAS).

Industry: N/A

Domainclival.com

Year Founded2013

Employees51 - 200

Annual Revenue--

Clival Database

Clival Database (including company regionals)

clival.com

See more website traffic and engagement information

Total visits to Clival Database's top domains

Understand Clival Database market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

clival.com10.8K

See more with Sales Intelligence

Avg. visit duration in Clival Database's top domains

Analyze Clival Database engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

clival.com00:00:18

See more with Sales Intelligence

Avg. pageviews on Clival Database's top domains

See how Clival Database keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

clival.com1.60

See more with Sales Intelligence

Clival Database top competitors by domain

Top similar sites in July 2026, ranked by their affinity

henlius.comCompany NameHenliusEmployees51 - 200HQUnited States, California, FremontAnnual revenue> $1BTotal visits28KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Clival Database

These are the website technologies, by industry, used by Clival Database top domains

Widget (5)

reCAPTCHA

Payment & Currencies (3)

Visa

Social (3)

Instagram

Conversion & Analytics (2)

Google Analytics

More Technologies

6

See all

News & Signals from Clival Database

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsClival partners with Emory Healthcare Hospital Group.Clival is thrilled to collaborate with Emory University, a leader in clinical research with a heritage of studying next-generation vaccines and cutting-edge technologies, and with the CDC, whose work to develop this novel vaccine and collaboration with Micron Biomedical to deliver it without needles has been ground-breaking.

NewsClival launches Actimab-A solid tumour programme.Additionally, Clival has launched its Actimab-A solid tumour programme to combine with PD-1 checkpoint inhibitors Keytruda and Opdivo for patients with head and neck squamous carcinoma and non-small cell lung cancer in multiple trials.

NewsClival launches combination therapy trial.Lifescience Intellipedia Pvt Ltd is therefore very excited to be launching this first combination therapy trial".